BRAF and melanoma: Using melanoma cells with intrinsic and acquired resistance to vemurafenib, we demonstrate here the combination of radiotherapy and a BRAF inhibitor to cause a radiation dose-dependent decrease in cell survival, and consequently an increase in cell death in vitro.